Li-Fraumeni Syndrome (LFS) is a rare, inherited disorder which leads to a higher risk of certain cancers, including sarcomas, brain tumors, breast cancer, and many others. It is inherited in an autosomal dominant manner and is often the result of heritable changes in the TP53 gene. The NCI has evaluated families with LFS since the syndrome was first recognized in 1969. DCEG is now expanding this research through a clinical study and participation in a multi-institutional collaboration. This LFS study is now open to patient enrollment. (LFS study protocol: 11-C-0255)
For more information, contact Sharon Savage.